Abstract Library

#4670 The efficacy of first-line combination therapy with everolimus plus lanreotide for gastroenteropancreatic neuroendocrine tumour with a poor prognostic factor: Updated and subgroup analysis of the phase III study, STARTER-NET (JCOG1901)

Introduction: Everolimus monotherapy provided a limited median progression-free survival (PFS) for gastroenteropancreatic neuroendocrine tumours (GEP-NETs), there remains a necessity for better therapeutic approaches.

Conference:

Presenting Author:

Authors: Hijioka S, Honma Y, Machida N, Mizuno N, Hamaguchi T,

Keywords: everolimus, lanreotide, PFS, RCT,

#4628 Triple negative breast neuroendocrine carcinoma in older patient: A rare entity

Introduction: Neuroendocrine breast carcinoma is a rare histological form of breast cancer, that represent 0.1% of all breast cancers and is recognised by the World Health Organization as a distinct entity. Characterised by a non-specific clinical and radiological presentation. Therapeutic management is not codified and is usually superimposed on that of classical breast cancer.

Conference:

Presenting Author:

Authors: Aris H, Saidi M, Lahfa I,

Keywords: neuroendocrine carcinoma, triple negative breast cancer, platinum-based combination therapy,

#4447 Efficacy and safety analysis of XELOX plus bevacizumab in the treatment of metastatic NETs

Introduction: For patients with advanced NETs, standardised treatment protocols based on guideline consensus form the foundation, yet individualised interpretation and flexible application of these guidelines are essential.

Conference:

Presenting Author: Wang H

Authors: Wang H, Zhou Y, Tan H, Sun Y, Chi Y,

Keywords: advanced neuroendocrine tumour, combination therapy, drug therapy, retrospective study, combined chemotherapy targeting,

#4301 Case report on the effectiveness of combination therapy in highly aggressive resistant prolactinoma

Introduction: Prolactinomas represent 50% of pituitary neuroendocrine tumours (PitNET), aggressive prolactinomas represent 15% of them.

Conference:

Presenting Author:

Authors: Asanova A, Shutova A, Pigarova E, Dzeranova L,

Keywords: prolactinoma, IHC, Pit Net, chemotherapy,

#4104 Promising outcomes with surufatinib-vinorelbine combination therapy in lung cancer with neuroendocrine differentiation

Introduction: Lung cancer (LC) remains one of the most prevalent and deadly cancers worldwide. Neuroendocrine differentiation (NED) is observed in 25-33% of LC cases. NSCLC patients with NED (NSCLC-NED) often have worse outcomes, resembling SCLC behaviour.

Conference:

Presenting Author:

Authors: Chai M, Zhang Y, Wang Y, Lu Z, Xie J,

Keywords: NSCLC-NED, treatment, surufatinib, vinorelbine,